01Background ─ Foreshadowing from 2025
The events of June 2026 did not start out of the blue. There are multiple foreshadowings from 2025. First, the United States will tighten its semiconductor export regulations. NVIDIA's H100 and H20 shipping regulations to China have been revised many times in 2025. Second, there is a debate about whether AI models themselves should be subject to export controls. This continued within the government from the end of the Biden administration to the beginning of Trump's second term. Third, as Anthropic rapidly wins large contracts (PwC, AWS, Oracle, LangChain), its technology is seen as a national strategic asset. These will lead to regulatory implementation in June 2026.
02Early June: Draft regulations emerge
In early June 2026, Politico and Axios successively reported that the U.S. government is considering export restrictions on Anthropic Mythos/Fable. The source of the information was an anonymous comment from a government official, and the specific target countries were clearly specified as China and Russia. Fortune reports that at this stage, there were voices within Anthropic saying that the deal was ``a bolt out of the blue'' and that ``prior consultation was insufficient,'' and there was widespread unrest within the company.
Notably, Anthropic's CEO Dario Amodei made an unusual public statement at the same time the proposed regulations emerged. Speaking just before the G7 summit, he said he would "appeal to the G7 to avoid fragmentation in AI governance." This can be interpreted as an attempt to relax the content of the proposed regulations through pressure from diplomatic channels while they were still in the discussion stage.
03Mid-June: Official announcement of regulations
In mid-June, the U.S. Department of Commerce officially issued export restrictions on targeted AI models, including Anthropic's Mythos and Fable 5. Al Jazeera critically reported that this would "further deteriorate relations with allies," while Politico expressed concern that "the scope of the restrictions is too broad." The BBC reported the embarrassment on the European side, including the UK. The industry is concerned about indirect restrictions on European companies' use of the Anthropic API.
Anthropic itself, within 24 hours of the regulation's announcement, carried out a suspension of access from foreign countries. This was a precautionary measure to comply with U.S. export regulations, and meant that internal discussions progressed in a short period of time. The range of countries covered by the suspension was gradually revealed, culminating in a broader restriction that included multiple countries.
04Late June ── Internal turmoil at Anthropic
A few days after the regulations were issued, complaints from within Anthropic that the company had been threatened by the Trump administration and that the regulations were unilaterally decided without prior consultation began to be leaked to multiple media outlets. In an exclusive report by Fortune, a portion of an internal meeting was reported in which Dario Amodei reportedly told employees, "This is a long-term trust issue."
Around the same time, news also broke that Anthropic had acquired John Jumper (Nobel Chemistry Prize winner and AlphaFold co-inventor) from Google DeepMind. This was an important acquisition in a time of regulatory turmoil, and it had the effect of demonstrating both internally and externally that Anthropic is committed to competing with its long-term research capabilities.
05Geopolitical context -- China's response
China's reaction was reported in parallel by the South China Morning Post (SCMP) and Bloomberg. Executives at Chinese AI startup DeepSeek and the CEOs of companies considered to be Chinese Anthropic rivals have successively declared, ``We will release a Fable 5-class model within a year.'' This became a declaration by the Chinese side, which was subject to restrictions, that it was trying to catch up in order to cut off its dependence on outsiders.
From a geopolitical perspective, this is an accelerated phase of the “US-China decoupling in AI” starting in 2024-2025. Semiconductors, AI models, international movement of researchers, regulation: On all axes, the United States and China are moving toward building parallel and independent ecosystems. The Fable regulation is one milestone in this major trend.
06Implications for the pharmaceutical industry
For the pharmaceutical industry, especially multinational pharmaceutical companies, the Fable regulation is no stranger. There is a risk that AI tools introduced under contract at the global headquarters will become unusable at each country's subsidiaries. There is a possibility that US AI will not be able to analyze clinical trial data. A structure in which the design of an international medical information response system is influenced by regulatory trends in each country. These are structural changes that force geopolitics to be taken into account from the technology selection stage.
Compliance and IT departments at pharmaceutical companies are nowgeopolitical risk assessment” perspective needs to be introduced. The evaluation criteria for selecting an AI vendor will need to include the item "multiple countries/dispersion of multiple vendors." Incorporating an architecture that does not rely too much on one company's or one country's AI from the early design stage will become the foundation that supports long-term business continuity.
07Review of this episode
The Anthropic Fable regulation in June 2026 symbolized that AI has become a matter of diplomacy rather than technology. Anthropic itself has been passive, and Dario Amodei's comments suggest embarrassment about regulation. Meanwhile, the US government has begun to use AI export controls as a viable option. China accelerates the construction of an independent ecosystem. Users, including the pharmaceutical industry, have no choice but to incorporate geopolitics into technology selection. The interests of all parties intersected during the week.
In the next article (part 7), we will consider from a longer-term perspective how Fable and Mythos will promote future AGI development in response to this regulation.